Stockscreener 앱 받기
13.76
4.44%
-0.64
시간 외 거래:
13.67
-0.09
-0.65%
전일 마감가:
$14.40
열려 있는:
$14.42
하루 거래량:
712.09K
Relative Volume:
0.66
시가총액:
$430.65M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+5.52%
1개월 성능:
-2.48%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$13.63
$14.50
1주일 범위
$12.56
$14.50
52주 변동 폭
$12.56
$21.47
Grail Inc Stock (GRAL) Company Profile
명칭
Grail Inc
전화
650-771-9796
주소
1525 O'BRIEN DRIVE, MENLO PARK
Grail Inc 주식(GRAL)의 최신 뉴스
Biotech company Grail to lay off 350, more than half in Bay Area - MSN
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success - Seeking Alpha
Closing Strong: GRAIL Inc. (GRAL) Ends at 13.04, Down -6.52 from Last Close - The Dwinnex
Gleeds to relocate to new Fitzrovia HQ - FMJ
Illumina and LGC Biosearch Technologies join forces to drive genomic innovation in agriculture - ANTARA English
Gleeds to move into new London HQ next January - Building
Ex-Linchpin director loses appeal of $150,000 penalty - Lawyerly
486 Shares in Graham Holdings (NYSE:GHC) Purchased by King Luther Capital Management Corp - Defense World
Illumina Wins Court Fight With EU Over $7 Billion Grail Deal - MSN
BreakingviewsLarry Fink’s private index dream may be holy grail - Reuters
John P. Mullen Sells 6,718 Shares of Guidewire Software, Inc. (NYSE:GWRE) Stock - Defense World
(09/18/24) GRAL: An Intriguing Biotech Name Active in Cancer Detection Test - Moneyshow.com
Illumina/Grail: EU Court overturns approach to “killer acquisitions” - JD Supra
With 59% ownership of the shares, GRAIL, Inc. (NASDAQ:GRAL) is heavily dominated by institutional owners - Simply Wall St
We're Keeping An Eye On GRAIL's (NASDAQ:GRAL) Cash Burn Rate - Yahoo Finance
Commission withdraws several decisions in the Illumina/GRAIL case - EU Reporter
Cœuré: Illumina/Grail decision will cause “more fragmented system” - Global Competition Review
Grail’s Potential Turnaround: Seeking FDA Approval For Galleri (NASDAQ:GRAL) - Seeking Alpha
GRAIL to focus on multi-cancer early detection; cuts workforce by 30% - MSN
Battery company says it's achieved breakthrough charging time with 'holy grail' of EV tech: 'This car [ticks] all the boxes' - The Cool Down
Illumina Wins Appeal in Europe Over Grail Acquisition, Avoids €432M Fine - Zenopa
Opinion | Illumina’s Antitrust Vindication - The Wall Street Journal
Illumina Wins EU Court Battle, Dodges Fine, but Grail Deal Already Void - geneonline
Illumina/GRAIL: ECJ Rules European Commission Lacks Jurisdiction to Review Merger Falling Below EU and National Merger Thresholds - Cleary Gottlieb
Illumina Wins Appeal Against European Commission - MD+DI
Below the thresholds but on the radar | What’s next after the ECJ's Illumina/Grail judgment? - Mayer Brown
EU’s Merger Powers Take Hit in Illumina-Grail Court Defeat - MSN
Cellular Health Screening Test Market Set to Witness Significant Growth by 2024-2031: GRAIL, Inc, OmegaQuant, - EIN News
Illumina avoids hefty EU fine over Grail merger - pharmaphorum
European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine - MSN
Illumina/Grail : EU Court Overturns Below-Threshold Merger Review Policy - Wilson Sonsini
European Court of Justice vacates decision in Illumina-Grail saga - BioWorld Online
Recon: Top EU court favors Illumina over EU regulators in Grail deal; US will still pay more for drugs than its peers after Medicare price negotiations - Regulatory Focus
Greek Regulator Investigates Novartis for Alleged Unfair Practices - PYMNTS.com
Illumina’s European Court Victory Can’t Salvage Grail Acquisition, But It Nullifies Hefty Fine - MedCity News
EU’s ability to challenge ‘killer acquisitions’ dealt a blow by Europe’s highest court - EURACTIV
Illumina wins court battle with EU over $7 billion Grail takeover - Business Standard
Illumina avoids fine for Grail purchase in European court victory - BioPharma Dive
Illumina avoids fine for Grail purchase in European court victory - MedTech Dive
EU high court hands Illumina consolation prize, ruling in favor of its appeal over Grail - Fierce Biotech
Illumina-Grail Deal Was Wrongly Probed by EU, Top Court Rules - Bloomberg
Illumina Wins Court Fight With EU Over $7 Billion Grail Takeover - MSN
European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine - Benzinga
Illumina Wins EU Top Court’s Support in Grail Acquisition - TipRanks
EU court backs Illumina and dismisses challenge over Grail acquisition - Medical Device Network
Critical News & Insights on European Politics, Economy, Foreign Affairs, Business & Technologyeuropeansting.com - The European Sting
EU’s merger powers take hit in Illumina-Grail court defeat - Luxembourg Times
Illumina wins Grail battle in blow to EU merger power - Yahoo Finance
Illumina wins Grail battle in blow to EU merger power - Reuters
Illumina wins legal battle over Grail deal in EU; avoids €432M fine - MSN
Grail Inc (GRAL) 재무 분석
Grail Inc (GRAL)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.62%
1.28%
자본화:
|
볼륨(24시간):